Active Efflux System for Cisplatin in Cisplatin-resistant Human KB Cells

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1994 Apr 1

PMID 8200854

Citations 14

Authors

R Fujii

M Mutoh

K Niwa

K Yamada

T Aikou

M Nakagawa

M Kuwano

S Akiyama

Affiliations

Soon will be listed here.

Abstract

Mutants, KCP-4 and PC-5, resistant to an anticancer agent, cisplatin, were selected in multiple steps from human epidermoid KB carcinoma cells and human prostate PC-3 carcinoma cells, respectively. KCP-4 and PC-5 were 63 and 10 fold more resistant to cisplatin than the parental cells, respectively. KCP-4 cells exhibited increased resistance to cisplatin analogues and were also slightly cross-resistant to melphalan, cyclophosphamide, mitomycin C and methotrexate. KCP-4 cells were not cross-resistant to doxorubicin, daunorubicin, vincristine or CdSO4. The accumulations of cisplatin in KCP-4 cells and PC-5 in medium containing 50 microM cisplatin were approximately 20% of those in the parental cells. Revertant analysis suggested that a defect in cisplatin accumulation may be related to cisplatin resistance in PC-5 cells. The uncoupling agent of oxidative phosphorylation, 2,4-dinitrophenol, increased the accumulation of cisplatin in KCP-4 and cisplatin-resistant human prostate carcinoma PC-5 cells to nearly the same level as in their parental KB-3-1 and human prostate carcinoma PC-3 cells without 2,4-dinitrophenol, but did not increase accumulation in KB-3-1 and PC-3 cells. Addition of glucose in the medium inhibited the enhancement of cisplatin accumulation in KCP-4 cells by 2,4-dinitrophenol. Enhanced active efflux of cisplatin from KCP-4 cells was observed. A cell-cell hybridization test showed that the cisplatin resistance and the accumulation defect behaved as codominant traits. These data suggest that an active efflux system for cisplatin exists in cisplatin-resistant KCP-4 cells.

Citing Articles

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells.

Lim Y, Kim H, Bae S, So K, Kim T, Lee J Molecules. 2024; 29(1).

PMID: 38202856 PMC: 10780346. DOI: 10.3390/molecules29010274.

The Role of Chloride Channels in the Multidrug Resistance.

Wilczynski B, Dabrowska A, Saczko J, Kulbacka J Membranes (Basel). 2022; 12(1).

PMID: 35054564 PMC: 8781147. DOI: 10.3390/membranes12010038.

Cell Death Induction and Protection by Activation of Ubiquitously Expressed Anion/Cation Channels. Part 1: Roles of VSOR/VRAC in Cell Volume Regulation, Release of Double-Edged Signals and Apoptotic/Necrotic Cell Death.

Okada Y, Sabirov R, Sato-Numata K, Numata T Front Cell Dev Biol. 2021; 8:614040.

PMID: 33511120 PMC: 7835517. DOI: 10.3389/fcell.2020.614040.

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells.

Li Y, Mao Y, Dong X, Lei Z, Yang Y, Lin L Front Oncol. 2020; 10:932.

PMID: 32676451 PMC: 7333678. DOI: 10.3389/fonc.2020.00932.

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.

Wu Z, Peng Z, Yang Y, Wang J, Teng Q, Lei Z Front Oncol. 2020; 10:674.

PMID: 32477940 PMC: 7235170. DOI: 10.3389/fonc.2020.00674.

References

Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K . Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res. 1989; 49(24 Pt 1):7020-5. View

Hromas R, North J, Burns C . Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 1987; 36(2):197-201. DOI: 10.1016/0304-3835(87)90091-7. View

Lai G, Ozols R, Young R, Hamilton T . Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst. 1989; 81(7):535-9. DOI: 10.1093/jnci/81.7.535. View

Andrews P, Velury S, Mann S, Howell S . cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988; 48(1):68-73. View

Lai G, Ozols R, Smyth J, Young R, Hamilton T . Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol. 1988; 37(24):4597-600. DOI: 10.1016/0006-2952(88)90325-5. View

Waud W . Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res. 1987; 47(24 Pt 1):6549-55. View

Kelley S, Basu A, Teicher B, Hacker M, Hamer D, Lazo J . Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988; 241(4874):1813-5. DOI: 10.1126/science.3175622. View

Nakagawa K, Yokota J, Wada M, Sasaki Y, Fujiwara Y, Sakai M . Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res. 1988; 79(3):301-4. PMC: 5917487. DOI: 10.1111/j.1349-7006.1988.tb01590.x. View

Ishikawa T . The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 1992; 17(11):463-8. DOI: 10.1016/0968-0004(92)90489-v. View

10.

Davidson R, GERALD P . Induction of mammalian somatic cell hybridization by polyethylene glycol. Methods Cell Biol. 1977; 15:325-38. DOI: 10.1016/s0091-679x(08)60223-x. View

11.

Masuda H, Ozols R, Lai G, Fojo A, Rothenberg M, Hamilton T . Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988; 48(20):5713-6. View

12.

Richon V, Schulte N, Eastman A . Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987; 47(8):2056-61. View

13.

Kraker A, Moore C . Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 1988; 48(1):9-13. View

14.

Weissman B, Stanbridge E . Characterization of ouabain resistant, hypoxanthine phosphoribosyl transferase deficient human cells and their usefulness as a general method for the production of human cell hybrids. Cytogenet Cell Genet. 1980; 28(4):227-39. DOI: 10.1159/000131536. View

15.

Kuppen P, Schuitemaker H, van t Veer L, de Bruijn E, Van Oosterom A, Schrier P . cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988; 48(12):3355-9. View

16.

Kawai K, Kamatani N, Georges E, Ling V . Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem. 1990; 265(22):13137-42. View

17.

Sheibani N, Jennerwein M, Eastman A . DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry. 1989; 28(7):3120-4. DOI: 10.1021/bi00433a055. View

18.

Mann S, Andrews P, Howell S . Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1990; 25(4):236-40. DOI: 10.1007/BF00684878. View

19.

Nakagawa M, Nomura Y, Kohno K, Ono M, Mizoguchi H, Ogata J . Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J Urol. 1993; 150(6):1970-3. DOI: 10.1016/s0022-5347(17)35948-7. View

20.

Loehrer P, Einhorn L . Drugs five years later. Cisplatin. Ann Intern Med. 1984; 100(5):704-13. DOI: 10.7326/0003-4819-100-5-704. View